Skip to main content
Medical information Clinical review pending

Genetic Testing

NIFTY NonInvasive Prenatal Testing (NIPT) Test

The NIFTY NonInvasive Prenatal Testing (NIPT) Test is a safe, non-invasive screening test for pregnant women to assess the risk of common chromosomal conditions like Down Syndrome, Edward Syndrome, and Patau Syndrome in the fetus using a maternal blood sample.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Maternal blood sample (approximately 10ml).
Results
Results are typically available within 8-10 days. Confirm with the laboratory before booking.
Preparation
No special preparation is required for this test. You can eat and drink normally before the blood draw.
Test priceKSh 20,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the NIFTY NonInvasive Prenatal Testing (NIPT) Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Pregnant women seeking screening for common chromosomal abnormalities.
  • ✓Expectant mothers aged 35 years or older.
  • ✓Women with a family history of chromosomal abnormalities.
  • ✓Individuals who have had abnormal results from other prenatal screenings.
  • ✓Those desiring early risk assessment for Down Syndrome, Edward Syndrome, or Patau Syndrome.
  • ✓Women seeking a non-invasive prenatal screening option.
02

In plain language

What this test helps you understand

This test provides a risk assessment for specific chromosomal abnormalities (Trisomy 21, 18, and 13) in the fetus. It is a screening test, not diagnostic, and results should be interpreted by a healthcare professional.
The NIFTY NonInvasive Prenatal Testing (NIPT) Test is an advanced screening tool designed for expectant mothers to assess the risk of certain genetic conditions in their unborn child. Utilizing cutting-edge Next-Generation Sequencing (NGS) technology, this test analyzes fetal DNA present in the mother's blood sample, providing accurate results without posing any risk to the fetus. This test screens for Trisomy 21 (Down Syndrome), Trisomy 18 (Edward Syndrome), and Trisomy 13 (Patau Syndrome). Early detection of these chromosomal abnormalities helps parents make informed decisions regarding their prenatal care.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is required for this test. You can eat and drink normally before the blood draw.
SampleMaternal blood sample (approximately 10ml).
MethodologyNext-Generation Sequencing (NGS) analysis of cell-free fetal DNA isolated from maternal plasma.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test is a screening test and does not provide a definitive diagnosis. A positive result indicates an increased risk and requires confirmation through diagnostic procedures like amniocentesis or chorionic villus sampling (CVS). The test may not detect all chromosomal abnormalities or other genetic conditions. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Yes, the NIPT test is non-invasive and only requires a maternal blood sample. It poses no risk to the pregnancy or the fetus.
This test screens for Trisomy 21 (Down Syndrome), Trisomy 18 (Edward Syndrome), and Trisomy 13 (Patau Syndrome).
No, the NIPT test is a screening test. A positive result indicates an increased risk and requires confirmation with diagnostic testing like amniocentesis or CVS.
The NIPT test has a high detection rate and a low false-positive rate for the conditions it screens for, but accuracy can vary. Discuss the specific accuracy rates with your healthcare provider.
The test can typically be performed from 10 weeks of gestation onwards. Confirm with the laboratory before booking.
Results will be communicated through your healthcare provider. We will also provide a report directly to the ordering physician.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp